WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 22-Oct-2018 (data as of 18-Sep-2018)
Next overall update spring 2019
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 142
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 162

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 31'977  31'568  31'155  30'738  30'318  24'488  19'862  15'344 
Births 599  601  602  603  604  583  576  501 
Surviving infants 592  593  594  595  596  571  562  482 
Pop. less than 5 years 2'971  2'974  2'975  2'975  2'972  2'823  2'764  2'288 
Pop. less than 15 years 8'824  8'806  8'783  8'760  8'732  8'364  7'531  6'295 
Female 15-49 years 8'391  8'310  8'228  8'149  8'068  6'421  4'993  3'678 

Number of reported cases

(Click for retrospective incidence data for Venezuela (Bolivarian Republic of))
Diphtheria
ChartChart
  786  31  31 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  727  22  9'881  9'750 
Mumps
ChartChart
  81  50  156  69  15  5'851 
Pertussis
ChartChart
  21  555  1'389  3'247 
Polio*
ChartChart
  11 
Rubella
ChartChart
  13'927 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  28  129 
Tetanus (total)**
ChartChart
  16  23  14  12  27  99  476 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Venezuela (Bolivarian Republic of))
Vaccine year result method % card seen                                                
BCG 1999  90  MICS     99*  99*  99  95  95  99  82  72 
DTP1 1999  88  MICS     95  99*  98  88  90  92 
DTP3 1999  59  MICS     66  84  87  78  82  77  63  56 
DTP4          38  52  50  46 
IPV1          70  68 
HepB_BD          74  56  89  82  80  14 
HepB3          66  84  87  78  82 
Hib3          66  84  87  78  82 
JapEnc         
MCV1          96  88  92  89  85  84  62  50 
MCV2          59  53  52  50  38 
MenA         
PCV1          19  78 
PCV2          14  63 
PCV3          24 
Pol3 1999  40  MICS     79  82  87  79  82  86  72  95 
Rota1          21  67  90  81  83 
RotaC          18  47  84  76  77 
RCV1          96  88  92  89  85 
TT2plus          43  45  52  34  48 
PAB         
VAD1         
YFV          83  84  85  82  85  17 
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Venezuela (Bolivarian Republic of))
BCG
ChartChart
  99  99  99  97  95  99  82  72 
DTP1
ChartChart
  95  97  98  88  90  92  84  79 
DTP3
ChartChart
  84  84  87  78  82  77  63  56 
HepB3
ChartChart
  84  84  87  78  82 
HepB_BD
ChartChart
  56  56  64  72  80  14 
Hib3
ChartChart
  84  84  87  78  82 
IPV1
  70  68 
MCV1
ChartChart
  96  88  92  89  85  84  61  50 
MCV2
ChartChart
  59  53  52  50  38 
PCV3
  24 
Pol3
  79  82  87  79  82  86  72  95 
RCV1
ChartChart
  96  88  92  89  85  84 
RotaC
ChartChart
  18  47  84  76  77 
YFV
ChartChart
  83  84  85  82  85  17 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 335  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
94 
   
/
|
|
\
Greater or equal to 90% 28
From 80 to 89% 12
From 50 to 79% 44
Less than 50% 16
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 2, 4, 6, 18 months; 5 years; Yes
HepB_Adult 1st contact; +1, +6 months; Yes risk groups
HepB_Pediatric birth; Yes
Influenza_Adult >60 years; Yes and adults with chronic illness, pregnant women, health care workers
Influenza_Pediatric 6-23 months; Yes and children with chronic illness
IPV 2 months; Yes
MenBC 1st contact, +2 months; Yes outbreaks and risk groups
MMR 12 months; 5 years; Yes and 1 dose to international travellers
OPV 4, 6, 18 months; 5 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >60 years; + 5 years; Yes
Rabies 1st contact; +3, +7, +14, +28 days; Yes post-exposure and prophylaxis of health workers
Rotavirus 2, 4 months; Yes
Td 1st contact; +1, +6 months; +1, +1 year; Yes Y10 at school, CBAW, health personnel, chronic sick, elderly, other risk groups
YF 1 year; Yes and international travellers and boarder areas

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  Yes  Yes  Yes  Yes  No 
What years does the MYP cover? number NA    2014-2018  2015-2020  2013-2018     
Nº of districts with microplans that include activities to raise immunization coverage number         250 

System performance

Total Nº districts in country number 335  335  335  335  335  335  367 
Nº districts with DTP3 coverage >=80% number 134  256  247  192  178  188  189 
% of districts with DTP3 coverage >=80% From 0 to 100% 40  76  74  57  53  56  51 
Nº districts with measles (MCV1) coverage >=95% number 210  172  169  164  91  103  113 
% of districts with MCV1 coverage >=95% From 0 to 100% 63  51  50  49  27  31  31 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  Yes  Yes  Yes  No  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   100  100  100  100  100  99 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  Yes  No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.